Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$0.33
-5.7%		$0.34
$0.00
▼
$2.90
$14.27M-1.8232,861 shs100 shs
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
$0.98
-7.5%		$0.98
$0.46
▼
$1.69
$11.15M0.2320,996 shs51,461 shs
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
$0.54
+14.8%		$0.49
$0.28
▼
$2.06
$18.02M0.29231,632 shs301,500 shs
TENK
TenX Keane Acquisition
$0.64
-3.3%		$12.88
$9.54
▼
$49.00
$4.27MN/A65,453 shs272,302 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
0.00%+3.13%+10.00%-28.26%-86.90%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
0.00%+0.51%-2.00%+44.10%+58.06%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
0.00%+12.26%+12.33%-22.92%-23.51%
TENK
TenX Keane Acquisition
0.00%0.00%0.00%0.00%-62.22%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$0.33
-5.7%		$0.34
$0.00
▼
$2.90
$14.27M-1.8232,861 shs100 shs
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
$0.98
-7.5%		$0.98
$0.46
▼
$1.69
$11.15M0.2320,996 shs51,461 shs
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
$0.54
+14.8%		$0.49
$0.28
▼
$2.06
$18.02M0.29231,632 shs301,500 shs
TENK
TenX Keane Acquisition
$0.64
-3.3%		$12.88
$9.54
▼
$49.00
$4.27MN/A65,453 shs272,302 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
0.00%+3.13%+10.00%-28.26%-86.90%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
0.00%+0.51%-2.00%+44.10%+58.06%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
0.00%+12.26%+12.33%-22.92%-23.51%
TENK
TenX Keane Acquisition
0.00%0.00%0.00%0.00%-62.22%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
1.00
SellN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
0.00
N/AN/AN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
2.00
Hold$3.00456.17% Upside
TENK
TenX Keane Acquisition
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TENK, KTTA, ANEB, and BCLI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/17/2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/17/2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/24/2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/16/2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$3.00
6/1/2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/A$0.28 per shareN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/A($1.36) per shareN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/AN/AN/AN/A$1.49 per shareN/A
TENK
TenX Keane Acquisition
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$8.48M-$0.19N/AN/AN/AN/A-74.57%-68.96%9/23/2026 (Estimated)
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$11.62M-$1.65N/AN/AN/AN/AN/A-519.50%N/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
-$20.43M-$1.58N/AN/AN/AN/A-49.49%-46.81%N/A
TENK
TenX Keane Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest TENK, KTTA, ANEB, and BCLI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$0.29-$0.35-$0.06N/AN/AN/A
8/14/2026Q2 2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
-$0.16-$0.16N/A-$0.16$0.30 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/AN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/AN/AN/AN/AN/A
TENK
TenX Keane Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/A
6.24
6.24
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/A
0.21
0.21
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/A
26.25
35.41
TENK
TenX Keane Acquisition
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
28.40%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
14.33%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
23.92%
TENK
TenX Keane Acquisition
70.52%

Insider Ownership

CompanyInsider Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
80.60%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
11.15%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
1.50%
TENK
TenX Keane Acquisition
22.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
440.79 million7.91 millionNot Optionable
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
4011.38 million8.74 millionOptionable
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
333.41 million32.91 millionNot Optionable
TENK
TenX Keane Acquisition
N/A6.65 million5.13 millionNot Optionable

Recent News About These Companies

TenX Keane Acquisition - Right Stock (NASDAQ:TENKR) Insider Trades
July 14, 2026  |  benzinga.comhttps://www.benzinga.com/quote/TENKR/insider-trades
CTOR stock touches 52-week low at $0.9 amid market challenges
November 24, 2024  |  investing.comhttps://www.investing.com/news/company-news/ctor-stock-touches-52week-low-at-09-amid-market-challenges-93CH-3737880
How to Complete On This Day Robbie Keane
November 6, 2024  |  ign.comI
Citius Oncology Inc (CTOR)
October 17, 2024  |  investing.comhttps://www.investing.com/equities/tenx-keane-acquisition-balance-sheet
Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
August 14, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-08/62981781-citius-pharmaceuticals-inc-citius-pharmaceuticals-completes-merger-of-subsidiary-with-tenx-keane-to-form-citius-oncology-inc-008.htm
Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
August 6, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-08/62910554-citius-pharmaceuticals-inc-citius-pharmaceuticals-announces-tenx-keane-shareholder-approval-of-merger-with-citius-oncology-inc-008.htm
TenX Keane Acquisition Shares Rise After Merger Approval
August 5, 2024  |  marketwatch.comhttps://www.marketwatch.com/story/tenx-keane-acquisition-shares-rise-after-merger-approval-ed0df739
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
February 14, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/citius-pharmaceuticals-inc-reports-fiscal-213000650.html
TenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment Proposal
January 10, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/tenx-keane-acquisition-announces-contribution-192900926.html?.tsrc=rss
TenX Keane Acquisition (TENK)
October 31, 2023  |  investing.comhttps://www.investing.com/equities/tenx-keane-acquisition-news
Citius unit to merge with TenX Keane to form public company
October 26, 2023  |  msn.comhttps://www.msn.com/en-us/money/companies/citius-unit-to-merge-with-tenx-keane-to-form-public-company/ar-AA1iLj15
Matthew G. Keane
August 23, 2023  |  health.usnews.comhttps://health.usnews.com/physician-assistants/matthew-keane-2118069
TenX Keane Acquisition to extend date for completion of business combination
July 18, 2023  |  seekingalpha.comhttps://seekingalpha.com/news/3988513-tenx-keane-acquisition-to-extend-date-for-completion-of-business-combination
TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination
July 18, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/tenx-keane-acquisition-announces-extension-200000057.html?.tsrc=rss
Uncertainty Returns After BitGo Cancels Prime Trust Acquisition
July 8, 2023  |  bitcoinmagazine.comhttps://bitcoinmagazine.com/business/uncertainty-returns-after-bitgo-cancels-prime-trust-acquisition
Roy Keane outlines his "worry" for Man Utd ahead of FA Cup final vs Man City
June 26, 2023  |  mirror.co.ukM
PAY/BTC - TenX Bitcoin
May 13, 2023  |  investing.comhttps://www.investing.com/crypto/tenx/pay-btc
Margaret Keane
April 27, 2023  |  mutualart.comM
Epiphany Technology Acquisition Corp Ordinary Shares - Class A
January 6, 2023  |  morningstar.comM
Figure Acquisition Corp I - Ordinary Shares - Class A
December 14, 2022  |  money.usnews.comhttps://money.usnews.com/investing/stocks/faca-figure-acquisition-corp-i-ordinary-shares-class-a

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anebulo Pharmaceuticals stock logo

Anebulo Pharmaceuticals NASDAQ:ANEB

$0.33 -0.02 (-5.69%)
As of 08/21/2026 10:22 AM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Brainstorm Cell Therapeutics stock logo

Brainstorm Cell Therapeutics NASDAQ:BCLI

$0.98 -0.08 (-7.55%)
As of 08/21/2026 03:41 PM Eastern

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Pasithea Therapeutics stock logo

Pasithea Therapeutics NASDAQ:KTTA

$0.54 +0.07 (+14.77%)
As of 08/21/2026 04:00 PM Eastern

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

TenX Keane Acquisition NASDAQ:TENK

TenX Keane Acquisition does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on target businesses operating in Asia, excluding companies located or operating in mainland China, Hong Kong, or Macau. TenX Keane Acquisition was incorporated in 2021 and is based in New York, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas